The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

NCT02271906 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Poor Accrual

Conditions

Lung Cancer

Interventions

DRUG: BIBW 2992

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]